Fig. 6: E-cadherin-dependent repression of metastasis formation by BI 853520.

a Mice were orthotopically transplanted with E-cadherin-expressing MTflECad or with E-cadherin-deficient MTΔECad murine breast cancer cells. BI 853520 treatment was started at a primary tumor size of 100 mm³, and animals were sacrificed before the primary tumor reached a size of ~1500 mm³. BI 853520 significantly increased survival of mice transplanted with MTflECad cells, but not in mice transplanted with MTΔECad cells. b BI 853520 significantly increases the mean time to reaching termination criteria in mice transplanted with E-cadherin-proficient MTflECad cells, but not in mice transplanted with E-cadherin-deficient MTΔECad cells. Statistical analysis was performed using a log-rank (Mantel–Cox) test. MTflECad: vehicle cohort, n = 8; BI 853520 cohort, n = 7. MTΔECad: vehicle cohort, n = 5; BI 853520 cohort, n = 6. c BI 853520 reduces the average numbers of pulmonary metastases per lung section in the cohort of mice bearing MTΔECad tumors. Vehicle cohort, n = 5; BI 853520 cohort, n = 6. Statistical analysis was performed using unpaired, two-tailed Student’s t test. All data are depicted as mean ± SEM. ****p < 0.0001